Literature DB >> 24315829

Landau-Kleffner syndrome: a study of 29 patients.

Roberto Horacio Caraballo1, Natalia Cejas2, Noelia Chamorro2, María C Kaltenmeier2, Sebastian Fortini2, Ana María Soprano2.   

Abstract

PURPOSE: The aim of the study was to retrospectively analyze the electroclinical features, etiology, treatment, and prognosis of 29 patients with Landau-Kleffner syndrome (LKS) with a long-term follow-up.
METHODS: Inclusion criteria were a diagnosis of LKS with: (1) acquired aphasia or verbal auditory aphasia; (2) with or without focal seizures, secondarily generalized tonic-clonic seizures, absences, or atonic seizures.
RESULTS: Mean follow-up was 12 years. All cases except six had seizures. Before the onset of aphasia, developmental language and behavioral disturbances were present in 19 and 14 patients, respectively. All patients had verbal auditory agnosia. Aphasia was severe in 24 patients and moderate in five. Nonlinguistic cognitive dysfunctions were moderate in 14 patients. Behavioral disturbances were found in 16 patients. During the continuous spike-and-wave discharges during slow sleep phase, the spike-wave index was >85% in 15, 50-85% in eight, and 30-50% in four. In two patients, the EEG recording showed occasional bilateral spikes, without continuous spike-and-wave discharges during slow sleep. In this phase, the awake EEG recording showed more frequent interictal abnormalities, predominantly in the temporal regions. Eight patients recovered language completely, but the remaining patients continue to have language deficits of different degrees.
CONCLUSION: Landau-Kleffner syndrome is an epileptic encephalopathy characterized by acquired verbal auditory aphasia and seizures in most of the patients associated with continuous or almost continuous spike-and-wave discharges during slow wave sleep. The most commonly used treatments were clobazam, ethosuximide, sulthiame. High-dose steroids were also administered. Adequate and early management may avoid language and cognitive deterioration.
Copyright © 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acquired aphasia; CSWS/ESES; Children; Landau–Kleffner syndrome; Treatment; Verbal auditory aphasia

Mesh:

Substances:

Year:  2013        PMID: 24315829     DOI: 10.1016/j.seizure.2013.09.016

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  7 in total

1.  Sulthiame add-on treatment in children with epileptic encephalopathy with status epilepticus: an efficacy analysis in etiologic subgroups.

Authors:  Seda Kanmaz; Erdem Simsek; Hepsen Mine Serin; Sanem Yilmaz; Gul Aktan; Hasan Tekgul; Sarenur Gokben
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

Review 2.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 3.  Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies.

Authors:  Rolla Shbarou
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

4.  Parent-Reported Sleep Profile of Children With Early-Life Epilepsies.

Authors:  Gita Gupta; Louis T Dang; Louise M O'Brien; Renée A Shellhaas
Journal:  Pediatr Neurol       Date:  2021-12-17       Impact factor: 3.372

Review 5.  Language Dysfunction in Pediatric Epilepsy.

Authors:  Fiona M Baumer; Aaron L Cardon; Brenda E Porter
Journal:  J Pediatr       Date:  2017-12-11       Impact factor: 4.406

6.  Treatment Practices and Outcomes in Continuous Spike and Wave during Slow Wave Sleep: A Multicenter Collaboration.

Authors:  Fiona M Baumer; Nancy A McNamara; Anthony L Fine; Elia Pestana-Knight; Renée A Shellhaas; Zihuai He; Daniel H Arndt; William D Gaillard; Sarah A Kelley; Margot Nagan; Adam P Ostendorf; Nilika S Singhal; Laura Speltz; Kevin E Chapman
Journal:  J Pediatr       Date:  2021-01-20       Impact factor: 4.406

7.  Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue.

Authors:  L Addis; J K Virdee; L R Vidler; D A Collier; D K Pal; D Ursu
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.